vs
Cue Biopharma, Inc.（CUE）与REDWOOD TRUST INC（RWT）财务数据对比。点击上方公司名可切换其他公司
REDWOOD TRUST INC的季度营收约是Cue Biopharma, Inc.的1.2倍（$25.9M vs $21.9M），REDWOOD TRUST INC净利率更高（77.2% vs 7.2%，领先70.0%），Cue Biopharma, Inc.同比增速更快（1292.3% vs -6.1%），过去两年Cue Biopharma, Inc.的营收复合增速更高（257.5% vs -41.0%）
Cue Biopharma是一家临床阶段生物技术企业，专注于开发针对癌症、自身免疫性疾病和炎症疾病的新型靶向免疫疗法，其专有平台可精准调节T细胞活性，主要业务覆盖北美地区，与全球药企合作推进核心候选产品的临床试验。
Redwood Trust Inc是总部位于美国的专业房地产投资信托公司，主营住宅与商业抵押贷款、抵押贷款支持证券及房地产信贷类资产的投资管理，核心业务覆盖住宅抵押贷款发放、商业地产信贷和投资服务，客户以机构投资者和房地产市场参与者为主。
CUE vs RWT — 直观对比
营收规模更大
RWT
是对方的1.2倍
$21.9M
营收增速更快
CUE
高出1298.3%
-6.1%
净利率更高
RWT
高出70.0%
7.2%
两年增速更快
CUE
近两年复合增速
-41.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.9M | $25.9M |
| 净利润 | $1.6M | $20.0M |
| 毛利率 | — | — |
| 营业利润率 | 9.0% | — |
| 净利率 | 7.2% | 77.2% |
| 营收同比 | 1292.3% | -6.1% |
| 净利润同比 | 116.7% | 402.6% |
| 每股收益（稀释后） | $0.05 | $0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CUERWT
| Q4 25 | $21.9M | $25.9M | ||
| Q3 25 | $2.1M | $15.0M | ||
| Q2 25 | $3.0M | $13.8M | ||
| Q1 25 | $421.0K | $27.9M | ||
| Q4 24 | $1.6M | $27.6M | ||
| Q3 24 | $3.3M | $25.5M | ||
| Q2 24 | $2.7M | $67.4M | ||
| Q1 24 | $1.7M | $74.5M |
净利润CUERWT
| Q4 25 | $1.6M | $20.0M | ||
| Q3 25 | $-7.4M | $-7.7M | ||
| Q2 25 | $-8.5M | $-98.5M | ||
| Q1 25 | $-12.3M | $16.1M | ||
| Q4 24 | — | $-6.6M | ||
| Q3 24 | $-8.7M | $14.8M | ||
| Q2 24 | $-10.2M | $15.5M | ||
| Q1 24 | $-12.3M | $30.3M |
营业利润率CUERWT
| Q4 25 | 9.0% | — | ||
| Q3 25 | -353.4% | -9.0% | ||
| Q2 25 | -292.3% | -679.0% | ||
| Q1 25 | -2921.4% | 80.2% | ||
| Q4 24 | — | -1.3% | ||
| Q3 24 | -264.2% | 86.1% | ||
| Q2 24 | -390.6% | 30.3% | ||
| Q1 24 | -737.8% | 41.3% |
净利率CUERWT
| Q4 25 | 7.2% | 77.2% | ||
| Q3 25 | -346.6% | -51.4% | ||
| Q2 25 | -287.1% | -712.0% | ||
| Q1 25 | -2911.4% | 57.8% | ||
| Q4 24 | — | -24.0% | ||
| Q3 24 | -259.6% | 58.1% | ||
| Q2 24 | -382.7% | 23.0% | ||
| Q1 24 | -719.1% | 40.6% |
每股收益（稀释后）CUERWT
| Q4 25 | $0.05 | $0.11 | ||
| Q3 25 | $-0.07 | $-0.08 | ||
| Q2 25 | $-0.09 | $-0.76 | ||
| Q1 25 | $-0.17 | $0.10 | ||
| Q4 24 | — | $-0.08 | ||
| Q3 24 | $-0.17 | $0.09 | ||
| Q2 24 | $-0.20 | $0.10 | ||
| Q1 24 | $-0.25 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.1M | $255.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $26.4M | $982.6M |
| 总资产 | $42.2M | $23.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CUERWT
| Q4 25 | $27.1M | $255.7M | ||
| Q3 25 | $11.7M | $226.3M | ||
| Q2 25 | $27.5M | $302.0M | ||
| Q1 25 | $13.1M | $259.9M | ||
| Q4 24 | $22.5M | $245.2M | ||
| Q3 24 | $32.4M | $253.7M | ||
| Q2 24 | $30.0M | $275.6M | ||
| Q1 24 | $41.0M | $275.4M |
总债务CUERWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | $1.7B |
股东权益CUERWT
| Q4 25 | $26.4M | $982.6M | ||
| Q3 25 | $13.2M | $999.0M | ||
| Q2 25 | $18.2M | $1.1B | ||
| Q1 25 | $6.6M | $1.2B | ||
| Q4 24 | $17.5M | $1.2B | ||
| Q3 24 | $25.4M | $1.2B | ||
| Q2 24 | $21.6M | $1.2B | ||
| Q1 24 | $30.0M | $1.2B |
总资产CUERWT
| Q4 25 | $42.2M | $23.7B | ||
| Q3 25 | $31.6M | $22.6B | ||
| Q2 25 | $40.7M | $21.3B | ||
| Q1 25 | $22.3M | $19.9B | ||
| Q4 24 | $32.2M | $18.3B | ||
| Q3 24 | $44.8M | $18.4B | ||
| Q2 24 | $42.3M | $16.5B | ||
| Q1 24 | $54.0M | $15.1B |
负债/权益比CUERWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | 1.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | $-10.1B |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | -0.68× | -504.15× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CUERWT
| Q4 25 | $-1.1M | $-10.1B | ||
| Q3 25 | $-9.0M | $-2.7B | ||
| Q2 25 | $-3.4M | $-2.1B | ||
| Q1 25 | $-8.2M | $-2.0B | ||
| Q4 24 | $-36.3M | $-5.9B | ||
| Q3 24 | $-7.5M | $-2.1B | ||
| Q2 24 | $-10.0M | $-2.0B | ||
| Q1 24 | $-9.8M | $-954.2M |
自由现金流CUERWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | $-8.3M | — | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-7.5M | — | ||
| Q2 24 | $-10.0M | — | ||
| Q1 24 | $-9.8M | — |
自由现金流率CUERWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -116.5% | — | ||
| Q1 25 | -1976.7% | — | ||
| Q4 24 | -2309.3% | — | ||
| Q3 24 | -225.7% | — | ||
| Q2 24 | -376.2% | — | ||
| Q1 24 | -573.0% | — |
资本支出强度CUERWT
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 35.6% | — | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 3.2% | — |
现金转化率CUERWT
| Q4 25 | -0.68× | -504.15× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -120.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -140.86× | ||
| Q2 24 | — | -126.56× | ||
| Q1 24 | — | -31.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
RWT
暂无分部数据
